FDA's Global Drug Control Inquiry Seeks Public Engagement Ahead Of WHO Summit

Original Article:

Source: Link

The U.S. Food and Drug Administration (FDA) has initiated public input regarding the potential international control of certain drugs, a move preceding the World Health Organization (WHO) Expert Committee on Drug Dependence (ECDD) meeting in October. Highlighted in the Federal Register, the FDA invites stakeholders and the public to contribute opinions on the international scheduling of specific drugs, a decision that holds broad implications for global drug regulations, as reported by Marijuana Moment (MM). Related Content: House Committee Chair To Question FDA Head On Hemp-Derived CBD, Medical Devices Notably, nitrous oxide, known as "laughing gas," used medically and recreationally, lacks an international classification. According to the FDA, "Nitrous oxide (N2O) is an inhalable gas... approved by FDA as a medical gas but has seen increasing use around the world for its subjective effects." Member states will assess whether nitrous oxide should undergo a preliminary review for possible international scheduling during the WHO ECDD meeting. Other substances under consideration include carisoprodol and six others like benzodiazepines, synthetic opioids, and stimulants, none of which are internationally controlled. Comments received will significantly influence the evaluation process. The U.S. Department of Health and Human Services (HHS) will incorporate inputs into a scientific assessment submitted to the WHO for its decision on international control, potentially impacting manufacturing, distribution, and record-keeping. Related Content: Biden Wants To See Marijuana Scheduling Review 'As Quickly As Possible,' Says HHS Top Official While the FDA seeks public input, its scheduling recommendation to the WHO awaits the latter's suggestion to the UN Commission on Narcotic Drugs, expected in late 2023. The FDA's call for comments concludes on August 24, allowing ample opportunity for engagement. When it comes to federal cannabis scheduling, there is no doubt that will be a burning topic among those at the 17th edition of the Benzinga Cannabis Capital Conference, which is returning to Chicago on Sept 27-28. Get your tickets today before prices increase and secure a spot at the epicenter of cannabis investment and branding. Image edited in Canva by El Planteo // Texture by Ilona Szentivanyi